EXPB9 Antibody

What is EXPB9 and what is its biological function?

EXPB9 (Expansin-B9) is a member of the expansin family, specifically the beta-expansin subfamily. It functions to facilitate fertilization by weakening the cell wall of the stigma and style, thereby promoting the penetration of the pollen tube. Its action is selective towards grass cell walls, which are characterized by a lower content of pectins and xyloglucans and a higher content of glucuronoarabinoxylans and (1-3),(1-4)-beta-D-glucans compared to the cell walls of other angiosperms. EXPB9 is primarily expressed in anthers and pollen, reinforcing its role in reproductive processes.

What are the common applications of EXPB9 antibodies in plant research?

EXPB9 antibodies are primarily used in the following applications:

• Western Blot (WB): For protein detection and quantification in plant tissue extracts

• Enzyme-Linked Immunosorbent Assay (ELISA): For quantitative detection of EXPB9 in various samples

• Immunohistochemistry: For localization studies in plant tissues

These applications help researchers study expansin expression patterns during plant development, stress responses, and reproductive processes .

How can EXPB9 antibodies be used to investigate cell wall modifications during pollen tube growth?

To investigate cell wall modifications using EXPB9 antibodies:

• Sample preparation: Collect pollen at different developmental stages and during pollen tube growth. Fix tissues using 4% paraformaldehyde in PBS for immunolocalization studies.

• Immunolocalization protocol:

  • Section fixed tissues (8-10 μm thickness)

  • Block with 5% BSA in PBS for 1 hour

  • Incubate with EXPB9 primary antibody (1:1000-1:3000 dilution)

  • Wash and apply fluorescent-conjugated secondary antibody

  • Counterstain cell walls with calcofluor white

  • Image using confocal microscopy

• Co-localization studies: Combine EXPB9 immunolocalization with other cell wall-modifying enzymes (e.g., xyloglucan endotransglycosylases, pectinases) to understand the temporal and spatial coordination of different cell wall-modifying activities.

• Biochemical analysis: Complement imaging with western blot analysis to quantify EXPB9 levels during different stages of pollen development.

This approach allows for temporal and spatial mapping of EXPB9 activity during pollen tube growth and provides insights into cell wall remodeling mechanisms.

What are the critical parameters for optimizing EXPB9 antibody specificity in cross-species applications?

When using EXPB9 antibodies across different plant species, consider these optimization parameters:

• Sequence homology analysis: Before experimental work, perform sequence alignment of EXPB9 across target species. Higher homology in the antibody's epitope region predicts better cross-reactivity.

• Antibody selection: Choose antibodies raised against conserved regions. Polyclonal antibodies purified by antigen affinity typically offer broader cross-reactivity than monoclonals .

• Blocking optimization:

  • Test different blocking agents (BSA, milk, serum)

  • Extend blocking time (2-4 hours) for tissues with high background

  • Include 0.1-0.3% Triton X-100 for better penetration

• Antibody validation methods:

  • Perform western blot with recombinant EXPB9 from target species

  • Include knockout/knockdown controls when available

  • Run peptide competition assays to confirm specificity

• Sample preparation modifications:

  • Adjust fixation times based on tissue type

  • Optimize antigen retrieval methods for each species

  • Consider species-specific protein extraction buffers

Testing these parameters systematically will help establish optimal conditions for cross-species applications .

How do post-translational modifications affect EXPB9 antibody recognition, and how can this be managed experimentally?

EXPB9, like other expansins, may undergo post-translational modifications (PTMs) including glycosylation, phosphorylation, and proteolytic processing that can significantly impact antibody recognition.

Impact of PTMs on antibody recognition:

• Glycosylation: Can mask epitopes or create steric hindrance, particularly in plant-produced EXPB9

• Phosphorylation: May alter epitope conformation or accessibility

• Proteolytic processing: The mature form of EXPB9 may lack signal peptides present in the full protein

Experimental management strategies:

• Enzymatic deglycosylation:

  • Treat samples with PNGase F or Endo H before immunodetection

  • Compare detection efficiency before and after treatment

  • Use lectin blotting in parallel to confirm glycosylation status

• Phosphatase treatment:

  • Treat protein extracts with lambda phosphatase

  • Compare antibody recognition before and after treatment

• Multiple antibody approach:

  • Use antibodies targeting different epitopes of EXPB9

  • Combine antibodies recognizing different regions (N-terminal vs. C-terminal)

• Recombinant standards:

  • Include E. coli-expressed EXPB9 (non-glycosylated) as control

  • Compare with yeast-expressed EXPB9 (partially glycosylated)

  • Use mammalian cell-expressed EXPB9 (complex glycosylation) when appropriate

• Mass spectrometry validation:

  • Confirm PTM status of your EXPB9 sample

  • Map modifications to specific amino acid residues

  • Correlate PTM locations with antibody binding sites

By implementing these strategies, researchers can gain a more comprehensive understanding of EXPB9 expression, processing, and modification patterns in different tissues and experimental conditions.

What are the most effective protein extraction protocols for EXPB9 detection by western blot?

Efficient extraction of EXPB9 from plant tissues requires specific considerations due to its cell wall association and potential membrane interactions. Here's an optimized protocol:

EXPB9 Extraction Protocol for Western Blot:

• Tissue preparation:

  • Collect 200-300 mg of fresh tissue (preferably anthers or pollen for highest yield)

  • Flash-freeze in liquid nitrogen

  • Grind to fine powder using mortar and pestle under liquid nitrogen

• Extraction buffer composition:

  • 50 mM Tris-HCl, pH 8.0

  • 150 mM NaCl

  • 1% Triton X-100

  • 0.5% sodium deoxycholate

  • 1 mM EDTA

  • 10% glycerol

  • Protease inhibitor cocktail (e.g., 1 mM PMSF, 1 μg/ml leupeptin, 1 μg/ml pepstatin A)

• Extraction procedure:

  • Add 4 volumes of cold extraction buffer to ground tissue

  • Vortex vigorously for 30 seconds

  • Incubate with gentle rotation at 4°C for 30 minutes

  • Centrifuge at 15,000 × g for 15 minutes at 4°C

  • Collect supernatant

  • (Optional) For enhanced extraction of membrane-associated EXPB9: sonicate samples briefly (3 × 10s pulses) before centrifugation

• Protein quantification:

  • Use Bradford or BCA assay, adjusting for detergent interference

  • Normalize samples to equal protein concentration

• SDS-PAGE preparation:

  • Mix samples with Laemmli buffer containing 100 mM DTT

  • Heat at 95°C for 5 minutes

  • Load 20-50 μg of total protein per lane

• Western blot conditions:

  • Transfer proteins to PVDF membrane (better than nitrocellulose for this application)

  • Block with 5% non-fat milk in TBST for 1 hour

  • Incubate with EXPB9 antibody at 1:1000-1:3000 dilution

  • Wash 3 × 10 minutes with TBST

  • Incubate with appropriate HRP-conjugated secondary antibody

  • Develop using enhanced chemiluminescence

This protocol has been shown to effectively extract both soluble and membrane-associated forms of EXPB9 for reliable western blot detection.

How can researchers develop genotype-phenotype linked antibody screening systems for EXPB9 variants?

Developing a genotype-phenotype linked antibody screening system for EXPB9 variants can be accomplished using an approach similar to that described in the NGS-compatible antibody presentation system . Here's a methodological framework:

• Library construction:

  • Design primers to amplify EXPB9 variant genes from diverse plant species or mutants

  • Include restriction sites (e.g., BsaI) for seamless cloning

  • Create a destination vector containing:

    • EF1a promoter

    • Venus reporter gene fusion

    • Membrane anchoring domain

• Assembly and expression:

  • Perform Golden Gate assembly to create expression constructs

  • Transfect constructs into mammalian cells (e.g., FreeStyle 293 or Expi293)

  • Express EXPB9 variants as membrane-displayed fusion proteins

• Antibody screening workflow:

  • Incubate antibody candidates with the cell display library

  • Perform flow cytometry to detect antibody binding to Venus-positive cells

  • Sort cells based on binding strength

  • Recover plasmids from sorted cells

  • Sequence to identify recognized EXPB9 variants

• Validation and characterization:

  • Produce soluble versions of identified EXPB9 variants

  • Perform binding kinetics analysis using surface plasmon resonance

  • Express and purify corresponding antibodies for further characterization

This methodology allows researchers to map epitope recognition patterns across EXPB9 variants and develop antibodies with desired specificity profiles for studying expansin biology across different plant species .

What strategies can be employed to overcome the challenge of detecting low-abundance EXPB9 in vegetative tissues?

Detecting low-abundance EXPB9 in vegetative tissues presents significant challenges due to its primary expression in reproductive tissues. The following strategies can enhance detection sensitivity:

• Sample enrichment techniques:

  • Perform subcellular fractionation to concentrate cell wall and membrane fractions

  • Use immunoprecipitation with existing EXPB9 antibodies

  • Apply ConA affinity chromatography to enrich glycosylated proteins

• Signal amplification methods:

  • Employ tyramide signal amplification (TSA) for immunohistochemistry

  • Use biotin-streptavidin amplification systems

  • Consider proximity ligation assay (PLA) for in situ detection

• Enhanced western blot sensitivity:

  • Utilize femto-level ECL substrates

  • Implement PVDF-FL membranes with fluorescent secondary antibodies

  • Apply gradient gels for better protein separation

• Advanced mass spectrometry approaches:

  • Use selected reaction monitoring (SRM) mass spectrometry

  • Employ targeted proteomics with synthetic EXPB9 peptide standards

  • Implement parallel reaction monitoring (PRM) for higher sensitivity

• Transcript-guided protein detection:

  • Perform RT-qPCR to identify tissues with detectable EXPB9 transcripts

  • Focus protein detection efforts on tissues with verified transcripts

  • Use polysome profiling to identify actively translated EXPB9 mRNA

By combining these approaches, researchers can overcome the challenge of detecting low-abundance EXPB9 in vegetative tissues, enabling more comprehensive studies of expansin distribution and function throughout plant development.

How should researchers address contradictory results between ELISA and western blot when detecting EXPB9?

Contradictory results between ELISA and western blot for EXPB9 detection are not uncommon due to the different nature of these techniques. Here's a systematic approach to address such discrepancies:

Root cause analysis:

• Epitope accessibility differences:

  • In ELISA: Proteins may retain native conformation

  • In western blot: Proteins are denatured, exposing different epitopes

• Cross-reactivity profiles:

  • Evaluate if the antibody recognizes related expansins in one assay but not the other

  • Test with recombinant EXPB9 and related expansins in both formats

• Post-translational modifications:

  • Determine if glycosylation affects antibody binding differently in each method

  • Test with deglycosylated samples in both assays

Methodological approach to resolve discrepancies:

• Validation with multiple antibodies:

  • Test several antibodies targeting different EXPB9 epitopes

  • Compare polyclonal vs. monoclonal antibody results

  • Include antibodies recognizing both N-terminal and C-terminal regions

• Control experiments:

  • Spike samples with recombinant EXPB9 at known concentrations

  • Calculate recovery rates in both methods

  • Include tissue samples from species without EXPB9 as negative controls

• Alternative confirmation methods:

  • Implement immunoprecipitation followed by mass spectrometry

  • Use competitive ELISA with purified EXPB9

  • Apply proximity ligation assays in tissues

Data integration framework:

By systematically investigating these factors, researchers can resolve contradictions and develop a more reliable detection strategy for EXPB9 across different experimental systems.

How can researchers distinguish between authentic EXPB9 signal and potential cross-reactivity with other expansin family members?

• Sequence similarity analysis:

  • Compile a database of all expansin family members in your species of interest

  • Perform sequence alignments to identify unique regions of EXPB9

  • Calculate percent identity between EXPB9 and other expansins

  • Pay special attention to closest family members (other beta-expansins)

• Competitive binding assays:

  • Pre-incubate antibody with recombinant EXPB9 before tissue application

  • Include recombinant related expansins (EXPB1, EXPB2, etc.) as competitors

  • Calculate percent signal reduction with each competitor

• Knockout/knockdown validation:

  • If available, use EXPB9 knockout/knockdown plants as negative controls

  • Compare signal reduction in these plants to wild-type

  • The remaining signal in knockout plants indicates cross-reactivity

• Peptide competition:

  • Synthesize unique peptides specific to EXPB9

  • Synthesize similar regions from related expansins

  • Pre-incubate antibody with each peptide before detection

  • Quantify signal reduction with each competing peptide

• Orthogonal detection methods:

  • Combine antibody detection with mass spectrometry

  • Use parallel reaction monitoring with EXPB9-specific peptides

  • Compare results between antibody-based and MS-based detection

Decision matrix for interpreting cross-reactivity:

How can EXPB9 antibodies be leveraged in functional genomics studies of cell wall dynamics during plant development?

EXPB9 antibodies can serve as powerful tools in functional genomics studies of cell wall dynamics through these methodological approaches:

• Chromatin immunoprecipitation (ChIP) adaptation:

  • Cross-link proteins to cell wall components in intact tissues

  • Fragment cell walls enzymatically or mechanically

  • Immunoprecipitate EXPB9-associated wall fragments

  • Analyze bound polysaccharides using comprehensive microarray polymer profiling (CoMPP)

  • This approach maps EXPB9's in vivo substrate preferences

• Developmental expression mapping:

  • Create tissue microarrays from plant developmental series

  • Perform high-throughput immunohistochemistry with EXPB9 antibodies

  • Quantify signal intensity across tissues and developmental stages

  • Correlate with transcriptome data from identical stages

  • Identify discrepancies indicating post-transcriptional regulation

• In situ activity correlation:

  • Combine EXPB9 immunolocalization with in situ wall extensibility measurements

  • Apply atomic force microscopy to measure local wall mechanical properties

  • Correlate EXPB9 abundance with nanomechanical wall properties

  • Map functional consequences of EXPB9 localization

• Protein-protein interaction networks:

  • Use EXPB9 antibodies for co-immunoprecipitation from cell wall extracts

  • Identify interacting proteins by mass spectrometry

  • Validate interactions using bimolecular fluorescence complementation

  • Construct interaction networks specific to different developmental stages

These approaches provide multidimensional insights into EXPB9's role in cell wall dynamics during plant development, connecting molecular mechanisms to physiological outcomes.

What considerations are important when developing EXPB9 antibodies for evolutionary studies across diverse plant lineages?

Developing EXPB9 antibodies for evolutionary studies requires special considerations to ensure reliable cross-species comparisons:

• Epitope conservation analysis:

  • Collect EXPB9 sequences from diverse plant lineages

  • Perform phylogenetic analysis to understand evolutionary relationships

  • Identify highly conserved epitopes preserved across lineages

  • Target conserved functional domains rather than variable regions

• Multi-epitope antibody strategy:

  • Develop multiple antibodies targeting different conserved regions

  • Create a panel of antibodies with complementary recognition patterns

  • Test each antibody against recombinant EXPB9 from representative species

  • Use antibody combinations tailored to specific lineage comparisons

• Calibration standards for quantitative comparisons:

  • Express recombinant EXPB9 from each major lineage

  • Create calibration curves specific to each species

  • Normalize detection sensitivity across lineages

  • Develop correction factors for cross-species comparisons

• Validation across evolutionary distance:

  • Test antibodies against species spanning increasing evolutionary distances

  • Map recognition patterns onto phylogenetic trees

  • Establish confidence thresholds for reliable detection

  • Document lineage-specific epitope variations

By implementing these strategies, researchers can develop EXPB9 antibodies suitable for evolutionary studies, enabling insights into expansin evolution and conservation across plant lineages.

How can antibody-based approaches be combined with single-cell techniques to study EXPB9 expression heterogeneity in plant tissues?

Integrating antibody-based approaches with single-cell techniques allows researchers to map EXPB9 expression heterogeneity with unprecedented resolution:

• Single-cell protein analysis workflows:

  • Enzymatically isolate protoplasts from plant tissues

  • Fix and permeabilize cells gently to preserve EXPB9 epitopes

  • Perform intracellular staining with fluorescently labeled EXPB9 antibodies

  • Analyze by flow cytometry to quantify cell-to-cell variation

  • Sort cell populations based on EXPB9 expression levels

  • Perform downstream transcriptomic analysis on sorted populations

• Spatial proteomics approaches:

  • Apply multiplexed immunofluorescence with EXPB9 antibodies and cell type-specific markers

  • Use spectral unmixing to resolve multiple fluorophores

  • Implement cyclic immunofluorescence for higher parameter analysis

  • Analyze images with cell segmentation algorithms to quantify single-cell expression

  • Preserve spatial context of EXPB9 expression heterogeneity

• Single-cell Western blot adaptation:

  • Capture individual protoplasts in microwell arrays

  • Lyse cells in situ and perform electrophoretic separation

  • Probe with EXPB9 antibodies using microfluidic systems

  • Quantify protein expression in hundreds of individual cells

  • Correlate with cell morphology or developmental stage

• In situ proximity ligation assay (PLA):

  • Detect EXPB9 interactions with other proteins at single-molecule resolution

  • Visualize protein complexes within intact tissues

  • Quantify interaction frequencies at the single-cell level

  • Map protein interaction networks with spatial resolution

These integrated approaches reveal not only which cells express EXPB9 but also how expression levels correlate with developmental state, cell identity, and physiological responses, providing a comprehensive understanding of EXPB9's role in plant development at single-cell resolution.

What emerging technologies might enhance EXPB9 antibody development and applications in the next 5 years?

Several emerging technologies are poised to transform EXPB9 antibody development and applications:

• Machine learning-guided antibody engineering:

  • Implementation of frameworks like AbMAP (Antibody Mutagenesis-Augmented Processing) to design antibodies with enhanced specificity

  • Deep learning models to predict epitope-paratope interactions

  • Algorithms to optimize antibody properties for specific applications

• Single-domain antibodies and nanobodies:

  • Development of camelid-derived nanobodies against EXPB9

  • Superior tissue penetration for in vivo imaging

  • Enhanced stability for field-deployable plant diagnostic applications

• CRISPR-engineered antibody validation systems:

  • Creation of epitope-tagged EXPB9 knock-in lines

  • Development of EXPB9 knockout plant lines as definitive negative controls

  • Implementation of CRISPR-based genetic screens to study EXPB9 function

• Spatially resolved proteomic approaches:

  • Integration with multiplexed ion beam imaging (MIBI) for high-parameter tissue analysis

  • Combination with spatial transcriptomics to correlate protein and mRNA distribution

  • Digital spatial profiling for quantitative in situ protein analysis

• Synthetic biology approaches:

  • Cell-free antibody display systems for rapid screening

  • Genotype-phenotype linkage technologies similar to those described for antibody screening

  • Synthetic receptor systems to monitor EXPB9 activity in real-time